355
Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study
Sunday, March 29, 2015: 7:00 AM
Salon C-D (Hilton Chicago)
S. E. Waggoner1, J. Java2, B. J. Monk3, H. Michael4, R. T. Penson5, M. M. Leitao6, R. L. Coleman7, R. S. Mannel8, A. Oaknin9 and K. S. Tewari10
1University Hospitals Case Medical Center, Cleveland, OH, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3University of Arizona Cancer Center, Phoenix, AZ, 4Indiana University School of Medicine, Indianapolis, IN, 5Massachusetts General Hospital/Harvard University, Boston, MA, 6Memorial Sloan Kettering Cancer Center, New York, NY, 7The University of Texas MD Anderson Cancer Center, Houston, TX, 8University of Oklahoma Health Sciences Center, Oklahoma City, OK, 9GEICO (Grupo Espanol de Investigacion en Cancer de Ovario), Barcelona, Spain, 10UC Irvine Medical Center, Orange, CA
